Gilead Sciences, Inc. · NASDAQ:GILD
Gilead Sciences — Merger or Acquisition (September 2020)
16 slides from Gilead Sciences's merger presentation, Sep 13, 2020
Slide 1: Gilead to Acquire Immunomedics
Gilead to Acquire Immunomedics September 13, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Immunomedics and the acquisition of Immunomedics by Gilead that are subject to risks, uncertainties and other factors. All
Slide 3: Gilead is Executing Upon our Corporate Strategy
Gilead is Executing Upon our Corporate Strategy Long-Term Ambitions Bring 10+ Transformative Be the Biotech Employer Deliver Shareholder Value in a Therapies to Patients by 2030 and Partner of Choice Sustainable, Responsible Manner Priorities Strategic Expand Internal and Strengthen Portfolio Contin
Slide 4: Gilead Acquires Immunomedics to Further Transform Oncology Portfolio
Gilead Acquires Immunomedics to Further Transform Oncology Portfolio Gilead to acquire Immunomedics c for a total purchase price of ~$21 billion Adds TrodelvyTM, a first-in-class antibody drug conjugate (ADC) approved for 3L+ metastatic triple-negative breast cancer (mTNBC)1 Significant efficacy ben
Slide 5: Strong Strategic Fit
Strong Strategic Fit Approved transformational medicine with potential to provide benefit across a broad range of solid tumors Accelerates entry into solid tumors with immediate presence in breast cancer Emerging data supports expansion into multiple solid tumors, including 3L+ HR+/HER2- metas
Slide 6: Expanding Gilead and Kite Oncology Pipeline with Immunomedics
Expanding Gilead and Kite Oncology Pipeline with Immunomedics Select pre-clinical Phase 1 Phase 2 Phase 3 Marketed GS-9716 SG SG SG Magrolimab Sacituzumab govitecan (SG) SG MCL1 inhib. Basket study 3L mTNBC 3L+ HR+/ Solid tumors mTNBC, mUC, Ovarian (+ PARPi) 3L+ UC Oncology (incl. NSCLC) (ASCENT) HE
Slide 7: Accelerating Buildout of Gilead and Kite Oncology Portfolio and Expertise
Accelerating Buildout of Gilead and Kite Oncology Portfolio and Expertise Building internal pipeline with 13 tailored transactions to access external innovation in last 2 years Zimberelimab (PD-1) PY314 (TREM2) Magrolimab (CD-47) Domvanalimab (TIGIT) TTX-080 (HLA-G) PY159 (TREM1) Etrumadenant (A2a/A
Slide 8: Trodelvy Overview
Trodelvy Overview Humanized anti-Trop-2 antibody • Trodelvy (sacituzumab govitecan) is the first ADC approved for r/r metastatic triple negative breast cancer • Targets Trop-2, an epithelial antigen expressed on a range - Highly specific antibody targets Trop-2, an epithelial antigen of solid tumors
Slide 9: Trodelvy Approved for 3L+ Metastatic Triple-Negative Breast Cancer
Trodelvy Approved for 3L+ Metastatic Triple- Negative Breast Cancer 3L Triple Negative Breast Cancer Ph. 3 (ASCENT, N=5291) • FDA granted accelerated approval in 3L+ mTNBC in PFS (months) April 2020 based on 33% ORR observed in Phase 1/2 5.62 IMMU-132-01 study3 • Confirmatory phase 3 ASCENT study st
Slide 10: Promising Clinical Data In Other Tumors
Promising Clinical Data In Other Tumors HR+/HER2- Metastatic Breast Cancer Metastatic Urothelial Cancer Ph. 1/2 (IMMU132-01) Ph. 1/2 (IMMU132-01); Ph. 2 (TROPHY U-01) ORR (%) PFS (months) ORR (%) PFS (months) 31%1 31%4 6.83 29%5 7.34 5.55 Historical Historical Historical Historical SOC data2 SOC dat
Slide 11: Multiple Opportunities to Improve Patient Outcomes with Trodelvy
Multiple Opportunities to Improve Patient Outcomes with Trodelvy Earlier Lines of Therapy Potential Expansion Indications Potential Combinations HR+/HER2- BC Checkpoint inhibitors Urothelial cancer PARP inhibitors NSCLC Other IO agents SCLC Gastric cancer Approved for Esophageal cancer 3L+ mTNBC Hea
Slide 12: Breadth of Trodelvy Studies Provides Opportunity for Expansion
Breadth of Trodelvy Studies Provides Opportunity for Expansion Trial Indication Phase 1 Phase 2 Phase 3 Approved IMMU-132-01 mTNBC (3L+) ASCENT mTNBC (3L) Study stopped early due to compelling efficacy TROPiCS-02 HR+/HER2- mBC (3L+) TROPHY U-01 Urothelial (3L+) Potentially registrational Basket (mNS
Slide 13: Key Near-Term Trodelvy Milestones
Key Near-Term Trodelvy Milestones ESMO 2020: Full Phase 3 sBLA submission for ASCENT data in 3L EU submission in full approval in metastatic metastatic triple-negative metastatic 3L triple-negative triple-negative breast breast cancer breast cancer cancer (to be presented 9/19) Q3 2020 Q4 2020 H1 20
Slide 14: Transaction Details
Transaction Details • Gilead to acquire Immunomedics for $88.00 per share in cash for a total purchase price of ~$21 billion - Tender offer is not subject to a financing condition c - Expect to fund acquisition with ~$15 billion of existing cash and ~$6 billion in newly issued debt - Does not alter
Slide 15: Trodelvy Supports Strategy to Drive Additional Growth and Complements YTD Progress
Trodelvy Supports Strategy to Drive Additional Growth and Complements YTD Progress Durable Core Existing Pipeline Strategy to Drive Business + Opportunities + Additional Growth Biktarvy #1 across markets Remdesivir for COVID-19 Trodelvy foundational asset for solid tumors Descovy for PrEP la
Slide 16: Thank You
THANK YOU CONTACT US investor_relations@gilead.com investors.gilead.com
Gilead Sciences — Merger or Acquisition (September 2020) on 6ix